COSMOS HEALTH INC (COSM)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$0.27+2.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · COSM
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute strategic expansion into the U.S. nutraceuticals market with the 18 Series platform and local manufacturing to drive growth.
Stated as a priority in 2 of last 2 quarters. Revenue grew from $13.7M in 2025-Q1 to $17.9M in 2026-Q1 (+30.7%), and from $14.7M in 2025-Q2 to $19.0M in 2026-Q2 (+28.8%). Management has emphasized U.S. expansion with the 18 Series platform and local manufacturing, and the trajectory shows delivering growth momentum consistent with this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We took our U.S. expansion from concept to execution with the 18 Series... expect the U.S. to become a principal growth engine.”
“A key pillar of growth is our entry into the lucrative U.S. nutraceuticals market through the 18 Series platform.”
Focus on reaching positive operating cash flow as a near-term financial milestone to mark a turning point in financial evolution.
Stated as a priority in 3 quarters including 2025-FY, 2026-Q1, and 2026-Q2. Operating cash flow remains negative, with -$1.07M in 2026-Q1 and -$1.72M in 2026-Q2, showing limited progress toward positive cash flow. Adjusted EBITDA improved but remains negative, indicating ongoing efforts but no positive cash flow yet.
“Continued progress toward profitability targets with adjusted EBITDA improving 13.8%.”
“Adjusted EBITDA near breakeven as increased revenue was offset by strategic investments.”
“Positive Operating Cash Flow: A central near-term milestone, marking a turning point in financial evolution.”
Target to grow total revenue to approximately $155.8 million by fiscal year 2027.
Stated as a priority in 3 quarters including 2025-FY, 2026-Q1, and 2026-Q2. Revenue grew from $54.4M in 2024 to $65.3M in 2025 (+20%), and the annualized run-rate exceeded $75M by 2026-Q2. The trajectory shows growth but remains below the $155.8M 2027 target, indicating ongoing progress toward this multi-year goal.
“Adjusted annualized revenue run-rate exceeding $75 million, a new milestone for Cosmos.”
“Record Q1 revenue of $17.9M, up 31%, with momentum continuing into Q2.”
“Revenue hits all-time record of $65.3M, up 20%, with strong momentum into 2026.”
Implement a Board-authorized share repurchase program of up to $5 million to enhance shareholder value.
Stated as a priority in 2 disclosures in 2026-Q2. The Board authorized a $5 million share repurchase program, with $1.11 million spent on repurchases by early Q3 2026. Management has executed the program actively, showing delivering progress consistent with the stated priority.
“Share repurchase program authorized for up to $5 million; $1.11 million spent as of early Q3 2026.”
“Board of Directors authorized a share repurchase program of up to $5 million expiring Dec 31, 2026.”
Over the trailing year it converted 0.19x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.